SCHEMBL6766727

SCHEMBL6766727

CCCC[Sn](CCCC)(CCCC)c1cncn1C(CC)N(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6767033 0.72 ALDH1A1 (0.32)
SCHEMBL253489 0.72 TBXAS1 (0.31)
SCHEMBL6766728 0.69 CYP2D6 (0.35)
SCHEMBL2156114 0.68 CYP1A2 (0.33)
SCHEMBL15529733 0.66 TBXAS1 (0.36)
SCHEMBL18586731 0.62 CYP11B1 (0.33)
SCHEMBL7630451 0.62 TBXAS1 (0.33)
SCHEMBL5254451 0.60 ALDH1A1 (0.42)
SCHEMBL30944028 0.60 DGAT1 (0.34)
SCHEMBL29893529 0.59 KDM4E (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828320-B2 Enzyme inhibitors; anticancer agents SMITHKLINE BEECHAM CORPORATION 2004-12-07 US disclosed
US-20020147214-A1 Heterocyclic compounds NOVARTIS AG (CH) 2002-10-10 US disclosed
US-6391874-B1 ANTICARCINOGENIC AGENTS; SKIN DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-05-21 US disclosed